The independent Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) examines the benefits and harms of medical interventions for patients.
What is the purpose of the dossier assessments that IQWiG prepares as part of the "early benefit assessment" of new drugs according to AMNOG? How are they structured? What is examined - and what is not? This is explained in the information chart.
Download image in high resolution
+49 221 35685-151
+49 221 35685-158
Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.
Questions about commissions, publications and press releases can be sent to us via this form.